ELISA/assay

Tocilizumab (ACTEMRA) ELISA

KBI1022

1 x 96 well

Tocilizumab (ACTEMRA) ELISA

Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was developed by Hoffmann–La Roche and Chugai.

The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Tocilizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Tocilizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Tocilizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Tocilizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

ELISA

Assay Kits

Therapeutic Drug Monitoring

1 x 96 well

Tocilizumab

Tocilizumab

<2.5 ng/mL

2.5-160 ng/ml

100 uL

Serum, Plasma, Cell Culture Supernatants

2.5 hours

RUO

wet

2-8C